Literature DB >> 30069896

Review article: treating-to-target for inflammatory bowel disease-associated anaemia.

Laurent Peyrin-Biroulet1, Anthony Lopez1, J R Fraser Cummings2, Axel Dignass3, Trond Espen Detlie4, Silvio Danese5.   

Abstract

BACKGROUND: Iron deficiency has a high prevalence in inflammatory bowel disease (IBD) patients, with negative impact on quality of life and work capacity. AIM: To propose an innovative approach based on early intervention, treating to target and tight monitoring in the management of iron deficiency in IBD patients.
METHODS: We conducted a literature review on PubMed and Medline using pre-defined keywords and terms to identify relevant studies on iron deficiency in IBD.
RESULTS: Many physicians are focused on treating anaemia; however, anaemia is one of the consequences of iron deficiency. Hence, our therapeutic goal for these patients should evolve towards prevention of anaemia by screening and treating iron deficiency. Early diagnosis of iron deficiency is based on a combination of ferritin concentration and transferrin saturation. We consider that normalisation of these biomarkers reflects iron stores replenishment and should be considered as a major therapeutic goal. Treating iron deficiency regardless of the presence of anaemia seems to improve quality of life in several chronic conditions and should be considered as an innovative approach in IBD although strong evidence is still lacking. Tight monitoring is required to allow early detection of iron deficiency recurrence and to consider prompt additional iron supplementation.
CONCLUSION: We propose to extrapolate a three-step strategy (early detection and intervention, treating-to-target and tight monitoring) to the management of iron deficiency in IBD patients. Universally applied, this proactive approach is expected to result in better outcomes in IBD patients.
© 2018 John Wiley & Sons Ltd.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30069896     DOI: 10.1111/apt.14922

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  8 in total

1.  Ferric Carboxymaltose Improves the Quality of Life of Patients with Inflammatory Bowel Disease and Iron Deficiency without Anaemia.

Authors:  Jose María Huguet; Xavier Cortés; Marta Maia Boscá-Watts; Margarita Muñoz; Nuria Maroto; Marisa Iborra; Esther Hinojosa; María Capilla; Carmina Asencio; Cirilo Amoros; Jose María Paredes
Journal:  J Clin Med       Date:  2022-05-15       Impact factor: 4.964

2.  HIF1α-Dependent Induction of TFRC by a Combination of Intestinal Inflammation and Systemic Iron Deficiency in Inflammatory Bowel Disease.

Authors:  Raphael R Fagundes; Arno R Bourgonje; Shixian Hu; Ruggero Barbieri; Bernadien H Jansen; Nienke Sinnema; Tjasso Blokzijl; Cormac T Taylor; Rinse K Weersma; Klaas Nico Faber; Gerard Dijkstra
Journal:  Front Physiol       Date:  2022-06-08       Impact factor: 4.755

Review 3.  Leptin and Obesity: Role and Clinical Implication.

Authors:  Milan Obradovic; Emina Sudar-Milovanovic; Sanja Soskic; Magbubah Essack; Swati Arya; Alan J Stewart; Takashi Gojobori; Esma R Isenovic
Journal:  Front Endocrinol (Lausanne)       Date:  2021-05-18       Impact factor: 5.555

4.  Hypophosphataemia after ferric carboxymaltose is unrelated to symptoms, intestinal inflammation or vitamin D status.

Authors:  Wendy Fang; Rachel Kenny; Qurat-Ul-Ain Rizvi; Lawrence P McMahon; Mayur Garg
Journal:  BMC Gastroenterol       Date:  2020-06-10       Impact factor: 3.067

Review 5.  Fatigue in Inflammatory Bowel Diseases: Etiologies and Management.

Authors:  Angelica Nocerino; Andrew Nguyen; Manasi Agrawal; Anjali Mone; Komal Lakhani; Arun Swaminath
Journal:  Adv Ther       Date:  2019-11-23       Impact factor: 3.845

Review 6.  Iron deficiency screening is a key issue in chronic inflammatory diseases: A call to action.

Authors:  Patrice Cacoub; Gabriel Choukroun; Alain Cohen-Solal; Elisabeth Luporsi; Laurent Peyrin-Biroulet; Katell Peoc'h; Valérie Andrieu; Sigismond Lasocki; Hervé Puy; Jean-Noël Trochu
Journal:  J Intern Med       Date:  2022-05-03       Impact factor: 13.068

7.  Iron deficiency markers in patients undergoing iron replacement therapy: a 9-year retrospective real-world evidence study using healthcare databases.

Authors:  Patrice Cacoub; Gael Nicolas; Katell Peoc'h
Journal:  Sci Rep       Date:  2020-09-11       Impact factor: 4.379

Review 8.  Iron Deficiency Anemia in Celiac Disease.

Authors:  Valentina Talarico; Laura Giancotti; Giuseppe Antonio Mazza; Roberto Miniero; Marco Bertini
Journal:  Nutrients       Date:  2021-05-17       Impact factor: 5.717

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.